A shortened course of anticoagulation to treat deep venous thrombosis after total joint arthroplasty

Yach, Jeff; Yen, David; Yach, J; Yen, D
October 2000
Clinical & Investigative Medicine;Oct2000, Vol. 23 Issue 5, p318
Academic Journal
journal article
Objective: To study whether the course of anticoagulation therapy in patients who have deep venous thrombosis (DVT) after total joint arthroplasty can be shortened with a minimal risk of recurrence. Design: A case series. Setting: Kingston General Hospital, a university-affiliated tertiary care centre. Patients: Eleven patients who were found to have DVT after total hip or knee arthroplasty on colour duplex Doppler ultrasonography, who fulfilled the study criteria and gave their informed consent. Exclusion criteria included chronic predisposing factors for thromboembolic disease, revision arthroplasty and a previous DVT. Interventions: Anticoagulation with warfarin to achieve an International Normalized Ratio of 2.0 to 2.5, adjusted 3 times a week until resolution of the DVT by duplex ultrasonography. Clinical and ultrasonographic evaluation at 1 year to monitor DVT recurrence. Outcome Measures: Resolution and recurrence of the DVT. Results: All patients showed resolution of the DVT at their first follow-up ultrasonography (mean 34 days post-operatively). There was no clinical or ultrasonographic evidence of recurrence at 1 year. Conclusion: Further study of a shorter course of anticoagulation therapy in patients who suffer DVT after joint arthroplasty should be considered.


Related Articles

  • Is It Safe to Withhold Anticoagulation Based on a Single Negative Color Duplex Examination in Patients with Suspected Deep Venous Thrombosis? A Prospective 3-Month Follow-up Study. Noren, Anders; Ottosson, Eva; Rosfors, Stefan // Angiology;Sep/Oct2002, Vol. 53 Issue 5, p521 

    The aim of this study was to evaluate prospectively the clinical short-term outcome of patients with suspected deep venous thrombosis (DVT) and negative duplex investigation and to assess whether it is clinically safe to withhold anticoagulant therapy on the basis of a single negative color...

  • Rivaroxaban may offer safe, effective treatment of venous thrombosis.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p32 

    The article reports that rivaroxaban may improve the benefit-to-risk profile of anticoagulation and may also offer a single-drug approach to the continued and short-term treatment of venous thrombosis, which is based on a study conducted by R. Bauersachs and colleagues.

  • COMMENTARY. Scott, Ian // Evidence Based Medicine;May2003, p85 

    The author discusses aspects of venous thromboembolism (VTE) treatment wherein he thinks that a stable anticoagulant control is difficult to achieve in patients with cancer and VTE and are receiving warfarin because of drug interaction and hepatic dysfunction secondary to metastatic liver disease.

  • After a first episode of venous thromboembolism. Chesterman, C.N. // BMJ: British Medical Journal (International Edition);9/16/95, Vol. 311 Issue 7007, p700 

    Discusses the need to stop anticoagulant treatment to patients four to six after the first episode of venous thromboembolism. Effect of warfarin; Risk of recurrence; Identification of patients at greater risk of occurrence after the termination of oral anti coagulant treatment.

  • Anticoagulant drugs in the elderly: the risks usually outweigh the benefits. Scott, Peter J.W. // BMJ: British Medical Journal (International Edition);11/12/88, Vol. 297 Issue 6658, p1261 

    Examines the side effects of anticoagulant drugs after treating elderly patients. Use of the drugs for the treatment of venous thrombosis and pulmonary embolism; Prevention of embolic stroke; Use of phlebography for the diagnosis of the disease.

  • What to do after a second venous thromboembolism. Berkowitz, Henry D. // Cortlandt Forum;12/20/97, Vol. 10 Issue 12, p78 

    Focuses on the continued anticoagulation therapy of patients who have experienced two episodes of venous thrombosis. How long should patients remain on therapy; Risks of extended therapy.

  • Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. Ganz, David A.; Glynn, Robert J.; Mogun, Helen; Knight, Eric L.; Bohn, Rhonda L.; Avorn, Jerry; Ganz, D A; Glynn, R J; Mogun, H; Knight, E L; Bohn, R L; Avorn, J // JGIM: Journal of General Internal Medicine;Nov2000, Vol. 15 Issue 11, p776 

    Objective: Guidelines for oral anticoagulation after deep venous thrombosis (DVT) or pulmonary embolism (PE) have recommended that patients be anticoagulated for at least 3 months after hospital discharge. We sought to determine whether this recommendation was being followed and...

  • Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. Agnelli, Giancarlo; Prandoni, Paolo; Santamaria, Maria Gabriella; Bagatella, Paola; Iorio, Alfonso; Bazzan, Mario; Moia, Marco; Guazzaloca, Giuliana; Bertoldi, Adriano; Tomasi, Cristina; Scannapieco, Gianluigi; Ascani, Alessandra; Villalta, Sabina; Frulla, Michela; Mosena, Laura; Girolami, Antonio; Vaccarino, Antonella; Alatri, Adriano; Palareti, Gualtiero; Marchesi, Mario // New England Journal of Medicine;7/19/2001, Vol. 345 Issue 3, p165 

    Background: In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. Whether this benefit persists after anticoagulant therapy is discontinued is...

  • Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. Ridker, Paul M; Goldhaber, Samuel Z.; Danielson, Ellie; Rosenberg, Yves; Eby, Charles S.; Deitcher, Steven R.; Cushman, Mary; Moll, Stephan; Kessler, Craig M.; Elliott, C. Gregory; Paulson, Rolf; Wong, Turnly; Bauer, Kenneth A.; Schwartz, Bruce A.; Miletich, Joseph P.; Bounameaux, Henri; Glynn, Robert J. // New England Journal of Medicine;4/10/2003, Vol. 348 Issue 15, p1425 

    Background: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics